DR. JAMES TATE THIGPEN, MD
Osteopathic Medicine at State St, Jackson, MS
License number
Mississippi 05853
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
2500 NORTH State St, Jackson, MS 39216
Phone
(601) 984-5590
(601) 984-5599 (Fax)
(601) 984-5599 (Fax)
Personal information
See more information about JAMES TATE THIGPEN at radaris.comName
Address
Phone
4206 Katie St, Moss Point, MS 39563
316 Daniels St, Jackson, MS 39209
3551 Edwards Ave, Jackson, MS 39213
3601 Kings Hwy, Jackson, MS 39216
8002 Bethesda Rd, Crystal Springs, MS 39059
Professional information
See more information about JAMES TATE THIGPEN at trustoria.com
Dr. James T Thigpen - MD (Doctor of Medicine)
Dr. James T Thigpen - MD (Doctor of Medicine)
Hospitals:
University of Mississippi Health Care
2500 N State St, Jackson 39216
University of Mississippi Medical Center
2500 North State St, Jackson 39216
University of Mississippi Health Care
2500 N State St, Jackson 39216
University of Mississippi Medical Center
2500 North State St, Jackson 39216
2500 N State St, Jackson 39216
University of Mississippi Medical Center
2500 North State St, Jackson 39216
University of Mississippi Health Care
2500 N State St, Jackson 39216
University of Mississippi Medical Center
2500 North State St, Jackson 39216
Education:
Medical Schools
University Of Mississippi School Of Medicine
Graduated: 1969
University Of Mississippi School Of Medicine
Graduated: 1969
Method Of Diagnosing And Monitoring Malignant Breast Carcinomas
Method Of Diagnosing And Monitoring Malignant Breast Carcinomas
US Patent:
6670141, Dec 30, 2003
Filed:
Sep 25, 2001
Appl. No.:
09/962477
Inventors:
Charles F. Streckfus - Brandon MS
Lenora G. Bigler - Clinton MS
James Tate Thigpen - Jackson MS
Lenora G. Bigler - Clinton MS
James Tate Thigpen - Jackson MS
Assignee:
University of Mississippi Medical Center - Jackson MS
International Classification:
G01N 33574
US Classification:
435 723, 435 4, 435 71, 435 72, 435 721, 435 792, 435 793, 435 794, 435 795, 436501, 436 63, 436 64
Abstract:
A panel of biomarkers for the diagnosis and treatment of breast cancer was examined in the saliva of a cohort of 1) healthy women, 2) women with benign lesions of the breast and 3) women with diagnosed breast cancer. Recognized tumor markers c-erbB-2 (erb), cancer antigen 15-3 (CA 15-3), and tumor suppresser oncogene protein 53 (p53) were found in the saliva of all three groups of women. The levels of erb and CA 15-3 in the cancer patients evaluated, however, were significantly higher than the salivary levels of healthy controls and benign tumor patients. Conversely, pantropic p53 levels were higher in controls as compared to those women with breast cancer and those with benign tumors.
Method Of Diagnosing And Monitoring Malignant Breast Carcinomas
Method Of Diagnosing And Monitoring Malignant Breast Carcinomas
US Patent:
6972180, Dec 6, 2005
Filed:
Mar 1, 2000
Appl. No.:
09/914501
Inventors:
Charles F. Streckfus - Brandon MS, US
Lenora G. Bigler - Clinton MS, US
James Tate Thigpen - Jackson MS, US
Lenora G. Bigler - Clinton MS, US
James Tate Thigpen - Jackson MS, US
Assignee:
The University of Mississippi Medical Center - Jackson MS
International Classification:
G01N033/574, G01N033/53, G01N033/68
US Classification:
435 723, 435 4, 435 71, 435 72, 435 721, 435 792, 435 793, 435 794, 436501, 436 63, 436 64
Abstract:
A panel of biomarkers for the diagnosis and treatment of breast cancer was examined in the saliva of a cohort of 1) healthy women, 2) women with benign lesions of the breast and 3) women with diagnosed breast cancer. Recognized tumor markers c-erbB-2 (erb), cancer antigen 15-3 (CA 15-3), and tumor suppresser oncogene protein 53 (p53) were found in the saliva of all three groups of women. The levels of erb and CA 15-3 in the cancer patients evaluated, however, were significantly higher than the salivary levels of healthy controls and benign tumor patients. Conversely, pantropic p53 levels were higher in controls as compared to those women with breast cancer and those with benign tumors.
Method Of Diagnosing And Monitoring Malignant Breast Carcinomas
Method Of Diagnosing And Monitoring Malignant Breast Carcinomas
US Patent:
6294349, Sep 25, 2001
Filed:
Mar 1, 1999
Appl. No.:
9/259993
Inventors:
Charles F. Streckfus - Brandon MS
Lenora G. Bigler - Clinton MS
James Tate Thigpen - Jackson MS
Lenora G. Bigler - Clinton MS
James Tate Thigpen - Jackson MS
Assignee:
University of Mississippi Medical Ctr. - Jackson MS
International Classification:
G01N 33574, G01N 3353, G01N 33567, G01N 33566, G01N 3348
US Classification:
435 723
Abstract:
A panel of biomarkers for the diagnosis and treatment of breast cancer was examined in the saliva of a cohort of 1) healthy women, 2) women with benign lesions of the breast and 3) women with diagnosed breast cancer. Recognized tumor markers c-erbB-2 (erb), cancer antigen 15-3 (CA 15-3), and tumor suppresser oncogene protein 53 (p53) were found in the saliva of all three groups of women. The levels of erb and CA 15-3 in the cancer patients evaluated, however, were significantly higher than the salivary levels of healthy controls and benign tumor patients. Conversely, pantropic p53 levels were higher in controls as compared to those women with breast cancer and those with benign tumors.